Beam Therapeutics Inc (BEAM)

May 25, 2026

Gene Editing Sector Gains Momentum with Key Players CRISPR and Beam - Intellectia AI

May 25, 2026

May 25, 2026

Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? - The Motley Fool

May 25, 2026

May 25, 2026

What Were the Key Highlights from Beam's RBC Conference Presentation - Kavout

May 25, 2026

May 22, 2026

Beam Therapeutics Inc (BEAM) Stock Price, Quote, News & History - Benzinga

May 22, 2026

May 22, 2026

Trading the Move, Not the Narrative: (BEAM) Edition - Stock Traders Daily

May 22, 2026

May 22, 2026

BEAM Stock Price, Quote & Chart | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill

May 22, 2026

May 21, 2026

H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com UK

May 21, 2026

May 21, 2026

H.C. Wainwright reiterates Beam Therapeutics stock rating at buy By Investing.com - Investing.com South Africa

May 21, 2026

May 21, 2026

H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - Moomoo

May 21, 2026

May 20, 2026

Beam Therapeutics Inc. (BEAM) Presents at ATS 2026 International ConferenceSlideshow - Seeking Alpha

May 20, 2026

May 20, 2026

Beam Therapeutics eyes sickle cell BLA as Alpha-1 gene-editing program advances - MSN

May 20, 2026

May 20, 2026

Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances - Yahoo Finance

May 20, 2026

May 20, 2026

BEAM: Lead gene editing programs advance toward approval with strong efficacy, safety, and payer value - TradingView

May 20, 2026

May 20, 2026

Beam Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus

May 20, 2026

May 20, 2026

Two Programs That Could Make or Break Beam Therapeutics Inc (BEAM) Stock - Insider Monkey

May 20, 2026

May 20, 2026

BEAM Technical Analysis | Trend, Signals & Chart Patterns | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill

May 20, 2026

May 20, 2026

In Vivo Gene Editing Market is expected to Hit US$ 37.75 Billion - openPR.com

May 20, 2026

May 19, 2026

10 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey

May 19, 2026

May 19, 2026

Beam Therapeutics (BEAM) Is Down 12.0% After Narrowing Losses And Positive BEAM-302 Data Update – Has The Bull Case Changed? - Sahm

May 19, 2026

May 19, 2026

Beam Therapeutics Data Puts BEAM 302 And AAT Disease In Focus - Yahoo Finance

May 19, 2026

May 19, 2026

ADAR1 Capital Management, LLC's Beam Therapeutics Inc(BEAM) Holding History - GuruFocus

May 19, 2026

May 19, 2026

Beam Therapeutics (BEAM) Advances Phase 1/2 Trial for AAT Deficiency - GuruFocus

May 19, 2026

May 19, 2026

Verve Therapeutics : VERV - 24/7 Wall St.

May 19, 2026

May 18, 2026

Beam Therapeutics presents AATD gene therapy trial data at ATS - Investing.com UK

May 18, 2026

May 18, 2026

Beam Therapeutics presents AATD gene therapy trial data at ATS By Investing.com - Investing.com Australia

May 18, 2026

May 18, 2026

Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference - The Manila Times

May 18, 2026

May 18, 2026

One-time gene-editing AATD therapy BEAM-302 seeks accelerated FDA path - Stock Titan

May 18, 2026

May 18, 2026

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? - Yahoo Finance

May 18, 2026

May 17, 2026

BEAM Stock's Gains Fade Despite Promising Data Rare Liver Disease Treatment Data - Stocktwits

May 17, 2026

May 15, 2026

HC Wainwright Expects Lower Earnings for Beam Therapeutics - MarketBeat

May 15, 2026

May 15, 2026

BEAM News Today | Why did Beam Therapeutics stock go up today? - MarketBeat

May 15, 2026

May 15, 2026

BEAM's Q1 loss wider than expected, revenues beat estimates - MSN

May 15, 2026

May 14, 2026

Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 8%Should You Sell? - MarketBeat

May 14, 2026

May 14, 2026

Beam Therapeutics Stock Stumbles After Post-Rally Shakeout - TipRanks

May 14, 2026

May 13, 2026

BEAM Maintained by Bernstein -- Price Target Lowered to $39.00 - GuruFocus

May 13, 2026

May 13, 2026

AlphaDetect Partners with Beam Therapeutics to Enhance Detection Efforts - Intellectia AI

May 13, 2026

May 13, 2026

Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 – Company Announcement - Financial Times

May 13, 2026

May 13, 2026

Beam Therapeutics: Base Editing Is Moving From Platform Story To Regulatory Asset Story - Seeking Alpha

May 13, 2026

May 13, 2026

Bernstein Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Cuts Target Price to $39 - Moomoo

May 13, 2026

May 13, 2026

Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference - The Manila Times

May 13, 2026

May 13, 2026

Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 - Barchart.com

May 13, 2026

May 12, 2026

Beam Therapeutics to present sickle cell therapy data at EHA - Investing.com India

May 12, 2026

May 12, 2026

Beam Therapeutics to present sickle cell therapy data at EHA By Investing.com - Investing.com South Africa

May 12, 2026